iASPP preferentially binds p53 proline-rich region and modulates apoptotic function of codon 72-polymorphic p53

Nature Genetics

Volumn 38, Issue 10, 2006, Pages 1133-1141

  Bergamaschi, Daniele ^a,e   Samuels, Yardena ^a,f   Sullivan, Alexandra ^a   Zvelebil, Marketa ^a   Breyssens, Hilde ^a   Bisso, Andrea ^b   Del Sal, Giannino ^b   Syed, Nelofer ^c   Smith, Paul ^c   Gasco, Milena ^d   Crook, Tim ^c   Lu, Xin ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^d S CROCE E CARLE HOSPITAL   (Italy)

^e QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^f JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOPTOSIS STIMULATING PROTEIN OF P53; APOPTOSIS STIMULATING PROTEIN OF P53 INHIBITOR; ARGININE; PROLINE; PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CODON; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FAMILY; PROTEIN POLYMORPHISM;

AMINO ACID SEQUENCE; APOPTOSIS; ARGININE; BINDING SITES; BREAST NEOPLASMS; CARCINOMA; CELLS, CULTURED; CODON; CONSERVED SEQUENCE; FEMALE; GENE EXPRESSION REGULATION; HOMOZYGOTE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, GENETIC; PROLINE; REPRESSOR PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TYROSINE;

EID: 33749118677     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng1879     Document Type: Article

References (30)

1. Slee, E.A., O'Connor, D.J. & Lu, X. To die or not to die: how does p53 decide? Oncogene 23, 2809-2818 (2004).
2. Samuels-Lev, Y. et al. ASPP proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8, 781-794 (2001).
3. Bergamaschi, D. et al. iASPP oncoprotein is a key inhibitor of p53 conserved from worm to human. Nat. Genet. 33, 162-167 (2003).
4. Liu, Z.J., Zhang, Y., Zhang, X.B. & Yang, X. Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia 18, 880 (2004).
5. Zhang, X., Wang, M., Zhou, C., Chen, S. & Wang, J. The expression of iASPP in acute leukemias. Leuk. Res. 29, 179-183 (2005).
6. Agirre, X. et al. ASPP1, a common activator of TP53, is inactivated by aberrant methylation of its promoter in acute lymphoblastic leukemia. Oncogene 25, 1862-1870 (2006).
7. Lossos, I.S., Natkunam, Y., Levy, R. & Lopez, C.D. Apoptosis stimulating protein of p53 (ASPP2) expression differs in diffuse large B-cell and follicular center lymphoma: correlation with clinical outcome. Leuk. Lymphoma 43, 2309-2317 (2002).
8. Vives, V. et al. ASPP2 is a haploinsufficient tumor suppressor that cooperates with p53 to suppress tumor growth. Genes Dev. 20, 1262-1267 (2006).
9. Gorina, S. & Pavletich, N.P. Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. Science 274, 1001-1005 (1996).
10. Walker, K.K. & Levine, A.J. Identification of the novel p53 functional domain which is necessary for efficient growth suppression. Proc. Natl. Acad. Sci. USA 93, 15335-15340 (1996).
11. Zhu, J., Jiang, J., Zhou, W., Zhu, K. & Chen, X. Differential regulation of cellular target genes by p53 devoid of the PXXP motifs with impaired apoptotic activity. Oncogene 18, 2149-2155 (1999).
12. Baptiste, N., Friedlander, P., Chen, X. & Prives, C. The proline-rich domain of p53 is required for cooperation with anti-neoplastic agents to promote apoptosis of tumor cells. Oncogene 21, 9-21 (2002).
13. Venot, C. et al. The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. EMBO J. 17, 4668-4679 (1998).
14. D'Erchia, A.M., Pesole, G., Tullo, A., Saccone, C. & Sbisa, E. Guinea pig p53 mRNA: identification of new elements in coding and untranslated regions and their functional and evolutionary implications. Genomics 58, 50-64 (1999).
15. Noma, C., Miyoshi, Y., Taguchi, T., Tamaki, Y. & Noguchi, S. Association of p53 genetic polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese women. Cancer Lett. 210, 197-203 (2004).
16. Granja, F. et al. Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer. Cancer Lett. 210, 151-157 (2004).
17. Agorastos, T. et al. P53 codon 72 polymorphism and correlation with ovarian and endometrial cancer in Greek women. Eur. J. Cancer Prev. 13, 277-280 (2004).
18. de Oliveira, W.R. et al. Association of p53 arginine polymorphism with skin cancer. Int. J. Dermatol. 43, 489-493 (2004).
19. Matakidou, A., Eisen, T. & Houlston, R.S. TP53 polymorphisms and lung cancer risk: a systematic review and meta-analysis. Mutagenesis 18, 377-385 (2003).
20. Cenci, M. et al. p53 polymorphism at codon 72 is not a risk factor for cervical carcinogenesis in central Italy. Anticancer Res. 23, 1385-1387 (2003).
21. Dumont, P., Leu, J.I., Della Pietra, A.C. III, George, D.L. & Murphy, M. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat. Genet. 33, 357-365 (2003).
22. Gostissa, M. et al. The transcriptional repressor hDaxx potentiates p53-dependent apoptosis. J. Biol. Chem. 279, 48013-48023 (2004).
23. Siddique, M.M. Evidence for selective expression of the p53 codon 72 polymorphs: implications in cancer development. Cancer Epidemiol. Biomarkers Prev. 14, 2245-2252 (2005).
24. Trigiante, G. & Lu, X. ASPPs and Cancer. Nat. Rev. Cancer 6, 217-226 (2006).
25. Sjalander, A., Birgander, R., Kivela, A. & Beckman, G. p53 polymorphisms and haplotypes in different ethnic groups. Hum. Hered. 45, 144-149 (1995).
26. Sjalander, A., Birgander, R., Saha, N., Beckman, L. & Beckman, G. p53 polymorphisms and haplotypes show distinct differences between major ethnic groups. Hum. Hered. 46, 41-48 (1996).
27. Iwabuchi, K., Li, B., Bartel, P. & Fields, S. Use of the two-hybrid system to identify the domain of p53 involved in oligomerization. Oncogene 8, 1693-1696 (1993).
28. Slee, E.A. et al. The N-terminus of a novel isoform of human iASPP is required for its cytoplasmic localization. Oncogene (2004).
29. Bergamaschi, D. et al. ASPP1 and ASPP2: common activators of p53 family members. Mol. Cell. Biol. 24, 1341-1350 (2004).
30. Bergamaschi, D. et al. p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis. Cancer Cell 3, 387-402 (2003).